Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron

Status Recruiting

Clinical Trial Summary

Iron deficiency anaemia (IDA) in postoperative patients with confirmed preoperative iron deficiency (ID) in a population with planned major surgery who need fast replenishment of iron as judged by the treating physician will be treated with i.v. iron using Polyglucoferron, Ferric Carboxymaltose or oral iron

Clinical Trial Description

In this study, patients with confirmed and documented preoperative non-anaemic iron deficiency (diagnosis up to 28 days before surgery in routine pre-surgery monitoring) who develop anaemia within 12 to 72 hours after start of surgery (with additional confirmation at Baseline) and for whom fast replenishment of iron stores is necessary, will be included and substituted within 24h after Screening Visit/V1. Peri- or postoperative anaemia will be assessed as soon as possible but earliest 12 h after surgery. For short term safety analysis iron in urine will be measured in the first urine after the end of i.v. administration in the first 35 patients who are eligible for analysis in each i.v. treatment group. Only those patients are eligible for whom haematuria and/or proteinuria are excluded using dip stick test. The Ferric Carboxymaltose treatment arm will be closed if a sufficient number of patients is included for safety analysis.The study will then be continued for assessment of co-primary efficacy endpoint: The effectiveness of postoperative i.v. iron substitution with Polyglucoferron compared to conventional oral iron substitution with Ferrous sulfate (treatment 28 - 35 days) to normalize Hb-values or to increase Hb-values by at least 1.5 g/dl until visit 4 will be evaluated as well as patient related outcomes, such as the decreased need for allogenic blood transfusions. In addition, the well-being of the patient will be assumed to improve after treatment using the SF36 questionnaire. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03817957
Study type	Interventional
Source	Fraunhofer Institute for Molecular Biology and Applied Ecology
Contact	Anita Bulczak-Schadendorf, Phd
Phone	0049696301
Email	anita.bulczak-schadendorf@ime.fraunhofer.de
Status	Recruiting
Phase	Phase 3
Start date	September 18, 2018
Completion date	December 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06027801` - Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity	N/A
Completed	`NCT02282553` - Gastric Capsule Examination for Iron Deficiency Anaemia	N/A
Recruiting	`NCT05217836` - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Recruiting	`NCT04913649` - Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients	Phase 4
Completed	`NCT02176759` - Iron Absorption From Rice Fortified With Ferric Pyrophosphate	N/A
Completed	`NCT01438645` - ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy	N/A
Completed	`NCT01307007` - Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding	Phase 2
Completed	`NCT00982007` - Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)	Phase 3
Completed	`NCT00198848` - Iron Supplementation Among Adolescent Girls in India	N/A
Completed	`NCT01166451` - The Anemia Control Program: High or Low Iron Supplementation	N/A
Recruiting	`NCT03893045` - A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects	Phase 3
Completed	`NCT03819530` - Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study	N/A
Completed	`NCT03618914` - Anemia and Inflammation
Completed	`NCT03940430` - Lactoferrin Versus Ferrous Sulfate in Management of Iron Deficiency Anemia Among Female Medical Ain Shams Students	Phase 2/Phase 3
Withdrawn	`NCT03873584` - Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
Enrolling by invitation	`NCT03897673` - Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas	N/A
Active, not recruiting	`NCT04778072` - A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects	N/A
Completed	`NCT03237065` - Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia	Phase 3
Completed	`NCT05153278` - IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department
Completed	`NCT03238911` - Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency — IDA-II

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms